Evidence map›Paper›PMID 41619025›Full record

ArticleJournal of bone and mineral metabolism2026

The effects of sequential therapy using anti-resorptive agents after administering once-weekly teriparatide or twice-weekly teriparatide.

Hidehiro Matsumoto, Manabu Tsukamoto, Nobukazu Okimoto, Satoshi Ikeda, Masahiro Tanaka, Mitsugu Takahashi, Yoshiaki Ikejiri, Fumihiro Oha, Satoshi Mizuno, Keiichi Shigenobu and 2 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of bone and mineral metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Hidehiro MatsumotoDepartment of Orthopaedic Surgery, Sanzai Hospital, Saito, Japan.
Manabu TsukamotoDepartment of Orthopaedic Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, Japan. m-tsuka@med.uoeh-u.ac.jp.ORCID http://orcid.org/0000-0003-4577-5072
Nobukazu OkimotoOkimoto Clinic, Kure, Japan.
Satoshi IkedaDepartment of Orthopaedic Surgery, Ken-Ai Memorial Hospital, Onga, Japan.
Masahiro TanakaDepartment of Orthopaedic Surgery, MAZDA Hospital, Fuchu, Japan.
Mitsugu TakahashiTakahashi Orthopedics Clinic, Chitose, Japan.
Yoshiaki IkejiriDepartment of Orthopaedic Surgery, Shimura Hospital, Hiroshima, Japan.
Fumihiro OhaDepartment of Orthopaedic Surgery, Hakodate Central General Hospital, Hakodate, Japan.
Satoshi MizunoHanakawa Orthopedics Clinic, Sapporo, Japan.
Keiichi ShigenobuHaraya Orthopedics Clinic, Sapporo, Japan.
Akinori SakaiDepartment of Orthopaedic Surgery, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-Ku, Kitakyushu, Japan.
Junichi TakadaOsteoporosis Center, Sapporo Maruyama Orthopaedic Hospital, Sapporo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionStudies launched in Japan on once-weekly teriparatide (1/W-TPTD) and twice-weekly teriparatide (2/W-TPTD) are limited. Therefore, we examined the effects of sequential therapy using anti-resorptive agents after administering 1/W-TPTD and 2/W-TPTD using dual-energy X-ray absorptiometry (DXA) and DXA-based 3D modeling. MATERIALS AND

methodsThis was a multicenter retrospective study following a phase 3 clinical trial called the TWICE study. Two-year follow-up data were collected after administering 1/W-TPTD or 2/W-TPTD for 1 year (follow-up after the phase 3 clinical trial).

results20 subjects in the group of pre-treatments with 1/W-TPTD followed by sequential administration of bisphosphonate or denosumab (1/W-TPTD [BP/denosumab]), and 22 in the group 2/W-TPTD (BP/denosumab) were included in the analysis of changes in the BMD by post-treatment. In the 1/W-TPTD (BP/denosumab) group, a significant increase in L2-4 BMD was observed. In the 2/W-TPTD (BP/denosumab) group, a significant increase in total hip, neck, and L2-4 BMD values was observed. Analysis by 3D-SHAPER revealed that both the 1/W-TPTD (BP/denosumab) and 2/W-TPTD (BP/denosumab) groups demonstrated significant increases in cortical sBMD and vBMD 2 years after the initiation of post-treatment.

conclusionIn subjects who received 1/W-TPTD and 2/W-TPTD for about 1 year followed by sequential administration of BP or denosumab, significant improvements in BMD were continuously observed. Furthermore, significant improvements in cortical sBMD and vBMD were also demonstrated by analysis using 3D-SHAPER. Both 1/W-TPTD and 2/W-TPTD were effective in the treatment of osteoporosis by using anti-resorptive agents for sequential administration.

Indexed as

Bone Density Conservation AgentsTeriparatideAbsorptiometry, PhotonAgedBone DensityDenosumabDiphosphonatesDrug Administration ScheduleFemaleHumansMiddle AgedRetrospective StudiesBone Density Conservation AgentsDenosumabDiphosphonatesTeriparatide3D-DXA3D modelingBone strengthBone structureTeriparatide

Identifiers

PMID41619025
PMCPMC13246890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.